Plerixafor use in patients with sickle cell disease (SCD) who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

Document first published:
Page updated:
Topic:
Publication type:

This commissioning statement aims to standardise the criteria for plerixafor use for stem cell mobilisation in patients with sickle cell disease (SCD) who are eligible to receive treatment with exagamglogene autotemcel to optimise the use of limited resources and ensure equitable access for patients across England.

Document

Commissioning statement: Plerixafor use in patients with sickle cell disease (SCD) who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

Commissioning statement: Plerixafor use in patients with sickle cell disease (SCD) who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

  • PDF
  • 190 KB

Summary

Published 25 February 2025.

Document

Equality and health inequalities impact assessment (EHIA): Plerixafor use in patients with sickle cell disease (SCD) who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

Equality and health inequalities impact assessment (EHIA): Plerixafor use in patients with sickle cell disease (SCD) who are eligible for treatment with exagamglogene autotemcel (ages 12 years and above)

  • PDF
  • 188 KB

Summary

Published 25 February 2025.